MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.39 2.96

Buy Sell

Overview

Share price change

24h

Current

Min

1.3599999999999999

Max

1.4

Key metrics
By Trading Economics
Income	-124K -32M
Sales	-372K 1.4M
EPS	-0.27
Profit margin	-2,364.792
Employees	161
EBITDA	-13M -42M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+45.99% upside

Dividends
By Dow Jones
Next Earnings	11 maj 2026

Market Stats
By TradingEconomics
Market Cap	-22M 152M
Previous open	-1.57
Previous close	1.39

News Sentiment

By Acuity

34%

66%

110 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 kwi 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 kwi 2026, 18:15 UTC

Major News Events

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 kwi 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 kwi 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 kwi 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 kwi 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 kwi 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 kwi 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 kwi 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 kwi 2026, 20:11 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 kwi 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

17 kwi 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 kwi 2026, 19:31 UTC

Market Talk

Major News Events

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 kwi 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 kwi 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 kwi 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 kwi 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 kwi 2026, 18:57 UTC

Major News Events

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 kwi 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 kwi 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB 2026 Rev Guidance Unchanged

17 kwi 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 kwi 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 kwi 2026, 18:14 UTC

Market Talk

Major News Events

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 kwi 2026, 18:00 UTC

Major News Events

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 kwi 2026, 18:00 UTC

Major News Events

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 kwi 2026, 17:31 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 kwi 2026, 17:26 UTC

Market Talk

Earnings

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

45.99% upside

12 Months Forecast

Average 2 USD 45.99%

High 2 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

110 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.